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Abstract
Preliminary data mostly from animal models suggest the sST2/IL-33 pathway may have causal relevance for vascular disease
and diabetes and thus point to a potential novel inflammatory link to cardiometabolic disease. However, the
characterisation of sST2 levels in terms of metabolic or vascular risk in man is completely lacking. We sought to address
this gap via a comprehensive analysis of risk factor and vascular correlates of sST2 in a cross-sectional study (pSoBid). We
measured sST2 in plasma in 639 subjects and comprehensively related it to cardiovascular and diabetes risk factors and
imaged atherosclerosis measures. Circulating sST2 levels increased with age, were lower in women and in highest earners.
After adjusting for age and gender, sST2 levels associated strongly with markers of diabetes, including triglycerides [effect
estimate (EE) per 1 standard deviation increase in sST2:1.05 [95%CI 1.01,1.10]), liver function (alanine aminotransaminase
[ALT] and c-glutamyl transferase [GGT]: EE 1.05 [1.01,1.09] and 1.13 [1.07,1.19] respectively), glucose (1.02 [1.00,1.03]) and
sICAM-1 (1.05 [1.02,1.07]). However, sST2 levels were not related to smoking, cholesterol, blood pressure, or atheroma
(carotid intima media thickness, plaque presence). These results suggest that sST2 levels, in individuals largely without
vascular disease, are related principally to markers associated with diabetes and ectopic fat and add support for a role of
sST2 in diabetes. Further mechanistic studies determining how sST2 is linked to diabetes pathways may offer new insights
into the inflammatory paradigm for type 2 diabetes.
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Introduction
Type 2 diabetes (T2D) is now a global epidemic associated with
increased risk of cardiovascular disease (CVD), including coronary
heart disease and stroke and selected cancers [1,2]. The prediction
of diabetic risk in the general population continues to be a major
challenge. The identification of additional novel biomarkers will
serve to elucidate underlying pathophysiological mechanisms, and
may allow prediction of downstream complications or the
identification of sub-groups of patients exhibiting distinct thera-
peutic responses [3]. A large body of evidence points towards the
involvement of subclinical, low-grade inflammation and activation
of the innate immune system, including increased systemic levels of
acute phase proteins, cytokines and adhesion molecules in patients
with T2D [4,5].
ST2 (also known as IL-1RL1, OMIM *601203) is a member of
the Toll-like/Interleukin (IL)-1 cytokine receptor super-family [6].
The ST2 gene encodes 2 protein isoforms formed by alternative
mRNA splicing. ST2L is a trans-membrane receptor comprising 3
linked extracellular immunoglobulin domains, a single trans-
membrane domain, and an intracellular Toll-interleukin-1 receptor
(TIR) domain homologous to toll-like receptors, which signal
through IL-1RAcP. Soluble ST2 (sST2) is a secreted form lacking
the trans-membrane and intracellular domains, and is thought to
function as a decoy receptor. The ligand for ST2 is IL-33 (also
known as IL-1F11), a recently identified member of the IL-1
cytokine family that exhibits a broad range of immune regulatory
functions [7]. IL-33 appears to exert protective cardiovascular effects
in mice, including reduced atherosclerotic burden in ApoE2/2mice,
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reduced adiposity with reduced fasting glucose and improved
glucose/insulin tolerance in ob/ob mice, and reduced cardiac
hypertrophy and fibrosis in a murine model of pressure overload
[8,9,10]. Furthermore, ApoE2/2 mice treated with sST2 developed
significantly larger atherosclerotic plaques in the aortic sinus
compared to control mice, and sST2 reversed the anti-hypertrophic
effects of IL-33 on cultured cardiomyocytes [10]. Thus, the soluble
form of ST2 may play an important role in negatively regulating a
putative protective role for IL-33 in the cardiovascular system. In
humans, elevated circulating levels of sST2 are associated with
adverse prognosis in patients with acute myocardial infarction (AMI)
[11,12] and heart failure [13,14]. Recently, some studies have shown
that sST2 levels are higher in patients with prevalent CVD who also
have diabetes [12,15,16,17]. However, so far the association between
sST2 levels with cardiometabolic markers has not been carefully
studied in any general population cohort.
We therefore sought to assess whether sST2 concentrations
correlated with classic and novel markers of cardiovascular and
diabetic risk in the cross-sectional psychological, social, and
biological determinants of ill health (pSoBid) study, a representa-
tive sample drawn from a major UK city. Our hypothesis, based
on protective effects of IL-33 with both vascular and metabolic
outcomes was that sST2 would be related to both cardiovascular
and diabetic risk factors and thus may be part of the common
pathways underpinning cardiometabolic outcomes.
Materials and Methods
Study Population and Protocol
Study members were participants in the cross-sectional pSoBid
study, established to test hypotheses directed at social determinants
of ill health in particular pertaining to vascular disease. The design
of the pSoBid study – including recruitment strategy, response
rates, and study protocol has been described in detail elsewhere
[18]. Briefly, 666 subjects (age 35–64 years) were recruited from 10
general practitioner practices within Glasgow, the largest city in
Scotland; of whom 639 had the necessary data for the present
analyses.
Participants were ranked on the basis of multiple deprivation
indicators to define the least and most deprived areas in the NHS
Greater Glasgow Health Board area, using criteria based on the
Scottish Index for Multiple Deprivation (SIMD), which ranks
small areas on the basis of multiple deprivation indicators across
six domains, namely: income; employment; health; education,
skills, and training; geographic access and telecommunications;
and housing. Sampling was stratified to achieve an approximately
equal distribution of the participants across males and females and
age groups (35–44, 45–54 and 55–64 years) within the most
(bottom 5% of SIMD score) and least deprived areas (top 20% of
SIMD score). Summaries of participant characteristics are
described in Tables S1.1, S1.2, S1.3. All subjects provided written
consent. The study complied with the Declaration of Helsinki, and
was approved by Glasgow Royal Infirmary Research Ethics
Committee.
Participants underwent assessment of their medical history,
undertook a physical examination (including measurement of
blood pressure, body mass index (BMI), waist:hip ratio) and
completed lifestyle questionnaires. Carotid ultrasound, to measure
intima-media thickness and plaque presence, were carried out as
previously described [18,19]. A sample of fasted blood was
collected and plasma was prepared, immediately frozen and stored
at 280uC. Later blinded batched analysis of risk factor status
included measurement of a range of classic (triglycerides,
cholesterol) and novel CVD risk factors (C reactive protein
[CRP], interleukin-6 [IL-6], soluble intercellular adhesion mole-
cule 1 [sICAM-1], estimate glomerular filtration rate [eGFR],
Fibrinogen) by methods as previously described [18,19]. B-type
natriuretic peptide [BNP] was measured on the Siemens ADVIA
Centuar using a two-site sandwich Immunoassay. N-terminal
[NT]-proBNP was measured on the Siemens Immulite using a
two-site chemiluminescent immunometric assay. Plasma sST2 was
quantified using a human IL-1 R4/ST2 DuoSet ELISA (R&D
Systems), with a lower limit of detection of 3.9 pg/ml and mean
intra-assay coefficient of variance (CV) of ,5% and mean inter-
assay CV of ,12%.
Statistical Analysis
Median sST2 levels (pg/ml) are presented graphically by gender
and age category (35–44, 45–54, 55–64 years). We determined the
associations between levels of sST2 in plasma and age, sex, and
their interaction using linear regression models of logarithmically
transformed sST2 as the outcome. We then assessed the
associations between plasma sST2 and lifestyle factors (body mass
index (BMI), physical activity, smoking, alcohol consumption and
monthly aggregate intake of fruit and vegetables) and measures of
socioeconomic status in adulthood (high or low Scottish Index of
Multiple Deprivation (SIMD 2004) score, annual income and
years of education) and in childhood (at 11 years of age: number of
siblings, number of people per room as a child and leg length),
using linear regression models adjusted for age, sex and their
interaction. Results are presented as the relative change in sST2
for specified changes in lifestyle and socioeconomic factors, with
95% confidence intervals (CIs) and p-values.
Linear regression models (logistic regression for plaque
presence) were then used to examine whether sST2 is a useful
predictor of classic and novel markers of cardiovascular and
diabetes risk, adjusted for age, sex and their interaction. Results of
linear models are presented as either the relative or absolute
change in the marker (depending on whether the marker was log-
transformed prior to modelling or not) associated with a one
standard deviation increase in log-transformed sST2, with a 95%
CI and p-value. For plaque presence, the odds ratio associated
with a one standard deviation increase in log-transformed sST2 is
presented, with a 95% CI and p-value.
A sensitivity analysis of the results to subject medication use
(either taking lipid lowering, anti-diabetic or anti-hypertensive
drugs or not) was conducted. Where a significant interaction
existed between sST2 and drug use as predictors, the drug use
status specific estimates are presented.
The statistical software package R for Windows v2.14 was used
for all analysis. No adjustments were made for multiple statistical
comparisons, so our p-values must be considered as descriptive
measures of the strength of evidence for the observed associations.
Significance levels of ,5% have been treated as suggestive of true
associations, with smaller p-values representing greater levels of
evidence.
Results
Plasma sST2 Levels Correlate with Age, Gender and
Income
The median sST2 levels in plasma within specified age
subgroups and split by gender are shown in Figure 1 and
geometric mean, median and interquartile range values shown in
Table S2. These data indicate overall higher sST2 concentrations
in males than females, which is highly significant after adjusting for
age (effect estimate 49% lower in women [95% CI 42% to 55%],
p,0.0001) (Table 1). Levels of sST2 were associated with age in
sST2 and Markers of Diabetes
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females only, with a relative increase of 24% (95% CI: 11.2% to
38.2%, p= 0.0001) for a 10 year increment in age, compared to a
relative change in men of +3.9% (27.0% to +16.3%), p= 0.50 (p-
value for interaction, 0.027). In Table 1 we show the relation of
sST2 with selected demographic, lifestyle, and socio-economic
variables. Further regression analysis did not reveal any association
of sST2 with markers of lifestyle such as body mass index (BMI),
activity level, smoking, alcohol or fruit and vegetable intake.
Analysis of markers of socioeconomic status (SES) demonstrated
that levels of sST2 were 21.2% (6.2% –33.7%, p= 0.0073) lower
in individuals with a salary .£45,000/annum in comparison to
those with a salary ,£15,000/annum independent of age and
gender. Levels of sST2 were not associated with other markers of
SES such as area deprivation, years of education or markers of
childhood deprivation (number of siblings, number of people per
room as a child and leg length).
Plasma sST2 Levels Correlate with Markers of Diabetic,
but not Cardiovascular, Risk
Associations between classic cardiovascular and diabetes risk
factors and sST2 levels are reported in Table 2 and interquartile
range values shown in Table S3. Individuals with higher sST2
levels had lower levels of HDL cholesterol, and increased levels of
triglycerides, systolic blood pressure and waist:hip ratio. However,
after adjustment for age, sex and their interaction, only the
association with triglycerides (5% (0.6% to 9.6%) increase in
triglycerides per one SD increase in log sST2, p= 0.025) was
evident. There was no evidence of associations between sST2 and
total or LDL cholesterol, or diastolic blood pressure.
Associations of sST2 levels with emerging or novel cardiovas-
cular and diabetes risk factors are shown in Table 3. Markers of
insulin resistance and dysglycaemia (fasting glucose, insulin and
the Homeostasis Model of Assessment [HOMA-IR]) all show signs
of being associated with sST2, though only glucose was significant
correlated following adjustment for age and sex (1.8% relative
increase for one SD increase in log sST2; 0.3% to 3.2%,
p= 0.019). Like other indices of obesity (BMI, waist:hip ratio)
leptin was not related to sST2 levels following adjustment for age
and sex (p= 0.066); the negative univariate association between
leptin and sST2 was explained by an association between leptin
and sex.
Despite being attenuated by age and sex adjustment, there were
strong associations between sST2 and markers of hepatic function,
with alanine aminotransaminase [ALT] and c-glutamyl transfer-
ase [GGT] showing relative increases of 4.8% (1.3% to 8.6%,
p= 0.0079) and 12.8% (6.9% to 19.1%, p,0.0001) for every SD
increase in log sST2, respectively. Such associations remained
robust to adjustment for alcohol intake (data not shown).
Of the markers of chronic inflammation (CRP, and IL-6) and
endothelial dysfunction (sICAM-1), sST2 showed a significant
association after age-sex adjustment only with sICAM-1, with a
relative increase of 4.9% (2.5% to 7.3%, p= 0.0001) per SD
increase in log sST2. There were no significant associations
between sST2 and the other novel risk factors Fibrinogen, Cystatin
C, eGFR, BNP, or NT-proBNP.
sST2 and Atherosclerotic/Plaque Measures
Finally, we examined the association between sST2 levels and
ultrasound measurements of atherosclerosis (common carotid
intima-media thickness [c-IMT] and plaque presence; Table 4).
We found a univariate association between sST2 and c-IMT
(p= 0.0002), but no significant association following adjustment
Figure 1. sST2 levels (pg/ml) by gender and age. Each box represents the median and upper/lower quartiles with the whiskers showing the 5th
and 95th percentiles.
doi:10.1371/journal.pone.0047830.g001
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Table 1. Associations (as relative effects) with 95% confidence intervals and p-values between sST2 as the outcome and selected
demographic, lifestyle and socio-economic status predictor variables univariately and adjusted for age, sex and their interaction*.
Predictor Variable Effect Estimate (95% CI), p-value
Univariate Adjusted
Demographic variables
Sex (Female vs. Male) at age 50 years 0.51 (0.45, 0.58), p,0.0001
Age** (per 10 year increase) Male Female 1.04 (0.93, 1.16), p = 0.5020 1.24
(1.11, 1.38), p = 0.0001
Lifestyle variables
BMI (per 5 kg/m2) 1.04 (0.98, 1.11), p = 0.1736 1.05 (0.99, 1.11), p = 0.1246
Waist Circumference (per 5 cm increase) 1.05 (1.02, 1.07), p = 0.0004 1.01 (0.99, 1.04), p = 0.2686
Hip Circumference (per 5 cm increase) 1.00 (0.97, 1.03), p = 0.7670 1.00 (0.97, 1.03), p = 0.8512
Waist: Hip Ratio (per 10% increase) 1.30 (1.19, 1.41), p,0.0001 1.08 (0.98, 1.18), p = 0.1015
Activity Level (vs. Inactive) Moderately Inactive
Moderately Active Active
0.81 (0.67, 0.99), p = 0.0421 0.82 (0.68, 0.98),
p = 0.0292 0.87 (0.72, 1.05), p = 0.1443
0.90 (0.74, 1.08),
p = 0.2555 0.92 (0.78, 1.10),
p = 0.3583 0.90 (0.75, 1.07), p = 0.2331
Smoking (vs. Non Smokers) Current Smokers 1.04 (0.88, 1.24), p = 0.6367 1.04 (0.89, 1.22), p = 0.5971
Diet Score per score of 10 0.99 (0.98, 1.00), p = 0.1203 1.00 (0.99, 1.01), p = 0.7401
Alcohol Consumption (weekly units) per 5 units 1.04 (1.02, 1.06), p = 0.0001 1.01 (0.99, 1.03), p = 0.1842
Adult Markers of Social Deprivation
Deprivation (vs. Least Deprived) Most Deprived 1.08 (0.94, 1.24), p = 0.2578 1.10 (0.97, 1.25), p = 0.1357
Annual Income (vs. ,15,000) 16–25,000 26–35,000
36–45,000 .45,000
0.97 (0.78, 1.21), p = 0.8174 0.92 (0.70, 1.19),
p = 0.5097 0.96 (0.73, 1.26), p = 0.7694 0.84 (0.70,
1.01), p = 0.0643
0.96 (0.78, 1.17), p = 0.6801 0.96
(0.75, 1.22), p = 0.7134 0.93 (0.72, 1.20),
p = 0.5645 0.79 (0.66, 0.94), p = 0.0073
Education (vs. #11 yrs) 12–13 yrs 14–16 yrs
$17 yrs
1.00 (0.82, 1.23), p = 0.9992 1.03 (0.86, 1.23),
p = 0.7675 0.97 (0.80, 1.17), p = 0.7111
1.08 (0.89, 1.31), p = 0.4270 1.06
(0.90, 1.26), p = 0.4713 0.90 (0.75, 1.07),
p = 0.2258
Childhood Markers of Social Deprivation
Number of Siblings (vs. None) 1–2 3 $4 0.89 (0.72, 1.09), p = 0.2557 0.92 (0.72, 1.19),
p = 0.5345 0.90 (0.70, 1.17), p = 0.4399
0.93 (0.76, 1.13), p = 0.4561 0.98
(0.78, 1.23), p = 0.8604 0.98 (0.77, 1.24),
p = 0.8628
People per Room (vs. #1) .1, #1.5 .1.5 1.12 (0.95, 1.33), p = 0.1818 1.07 (0.91, 1.27),
p = 0.4233
1.08 (0.92, 1.26), p = 0.3345 1.06
(0.90, 1.24), p = 0.4765
Leg Length (vs. #75 cm) 75.1–80 cm 80.1–85 cm
.85 cm
1.13 (0.91, 1.40), p = 0.2710 1.35 (1.09, 1.68),
p = 0.0061 1.57 (1.25, 1.98), p = 0.0001
0.95 (0.77, 1.17), p = 0.6134 0.91
(0.73, 1.15), p = 0.4290 0.93 (0.72, 1.20),
p = 0.5977
*Associations after adjustment for age and sex with interaction. Regression models were fitted with log sST2 as the outcome. Effect estimates are the relative change in
sST2 for a specified increase in continuous predictor variables, or compared to the stated reference group for categorical predictors.
**p-value = 0.0271 for the ineraction term of age and sex as predictors of log sST2.
doi:10.1371/journal.pone.0047830.t001
Table 2. Associations between classical cardiovascular and metabolic risk factors (outcomes) and sST2 (predictor), univariately and
adjusted for age and sex*.
Outcome Effect Estimate (95% CI), p-value
Univariate Adjusted
Total Cholesterol (mmol/l) 1.00 (0.98, 1.02) p = 0.8727 1.01 (0.99, 1.02) p = 0.4547
LDL-Cholesterol (mmol/l) 0.99 (0.97, 1.02) p = 0.6856 1.00 (0.97, 1.02) p = 0.7922
HDL-Cholesterol (mmol/l) 0.96 (0.94, 0.98) p=0.0003 0.99 (0.97, 1.02) p = 0.5649
Triglycerides (mmol/l) 1.08 (1.04, 1.13) p=0.0001 1.05 (1.01, 1.10) p =0.0250
Systolic BP (mmHg) 1.02 (1.01, 1.03) p=0.0002 1.01 (1.00, 1.02) p = 0.2683
Diastolic BP (mmHg) 1.01 (1.00, 1.02) p = 0.0642 1.00 (0.99, 1.02) p = 0.4205
*Regression models were fitted with classical risk factors as the outcome (all log transformed) and log sST2 as the predictor. Adjusted models include age, sex and their
interaction.
Effect estimates are reported as the relative change in outcome associated with a one standard deviation in log sST2.
doi:10.1371/journal.pone.0047830.t002
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for age and sex. There was no evidence of an association between
sST2 and plaque presence.
Sensitivity Analysis
Tables S4, S5, S6 and S7 show the results of repeating the
analysis adjusting for subject medication use. Subjects who were
receiving lipid lowering, anti-diabetic or anti-hypertensive medi-
cations had 25% higher sST2 levels compared to those who were
not. Associations between demographic and lifestyle variables and
sST2 levels remained after adjusting for medication use. Associ-
ations between sST2 and ALT, GGT and sICAM-1 were similar
to the main analysis, though sST2 was predictive of HDL-
cholesterol and glucose for subjects who were on medications only.
Discussion
The main finding of this study is that sST2, a decoy receptor for
the recently described IL-1 family member IL-33, correlates with
classic and novel markers of insulin resistance/endothelial
dysfunction. Abnormal glucose metabolism defines diabetes and
accounts for many of its symptoms and complications [20]. We
show that sST2 significantly correlates with glucose levels in a
general population. Our data extend a previous study showing
higher sST2 levels in patients with type 2 diabetes and left
ventricular dysfunction [16]. Furthermore, studies in patients with
myocardial infarction or heart failure also showed that sST2 levels
correlated with glucose [15], and were higher in patients with
diabetes versus those who did not have diabetes [12,15,17].
Importantly, we also show correlation of sST2 with other markers
linked to diabetes in addition to glucose. Circulating triglycerides,
markers of ectopic fat in blood that are also linked to insulin
resistance, correlated with sST2 levels, as did ALT and GGT,
markers of liver function. Elevated levels of ALT and GGT are
associated with T2D independent of other factors [21,22,23]. It is
likely that these elevations in liver enzymes reflect increasing fatty
liver and mechanisms linking excess hepatic fat with insulin
resistance are now well established [24] such that fatty liver is an
established risk factor for diabetes [25]. It is also important to
recognize potential relationships between glycaemia and heart
failure; sST2 is associated with prognosis of heart failure
[12,13,14]. Poor glycaemic control is a known biomarker of heart
failure severity and prognosis [26]. Furthermore, elevated GGT
was also recently shown to be associated with increased risk of
incident heart failure in men aged ,70 years [27]. The present
findings are therefore broadly consistent with a potential link
between diabetes pathways, sST2, and heart failure. They suggest
that the association of sST2 with heart failure prognosis may stem
from its associations with metabolic perturbances.
Table 3. Associations between novel cardiovascular and metabolic risk factors (outcomes) and sST2 (predictor), univariately and
adjusted for age and sex*.
Outcome Effect Estimate (95% CI), p-value
Univariate Adjusted
Glucose (mmol/l) 1.03 (1.01, 1.04) p=0.0002 1.02 (1.00, 1.03) p=0.0195
Insulin (U/l) 1.05 (1.00, 1.11) p = 0.0521 1.04 (0.98, 1.10) p = 0.1940
HOMA-IR 1.07 (1.01, 1.14) p=0.0164 1.05 (0.99, 1.12) p = 0.1246
Leptin (ng/ml) 0.87 (0.81, 0.94) p=0.0002 1.06 (1.00, 1.13) p = 0.0660
ALT (U/l) 1.12 (1.08, 1.16) p,0.0001 1.05 (1.01, 1.09) p=0.0079
GGT (U/l) 1.21 (1.15, 1.28) p,0.0001 1.13 (1.07, 1.19) p,0.0001
CRP (mg/l) 1.07 (0.98, 1.17) p = 0.1162 1.09 (1.00, 1.20) p = 0.0605
IL-6 (pg/ml) 1.07 (1.02, 1.13) p=0.0106 1.05 (0.99, 1.11) p = 0.0824
sICAM-1 (pg/ml) 1.05 (1.03, 1.07) p,0.0001 1.05 (1.02, 1.07) p=0.0001
Fibrinogen(a) (g/l) 0.03 (20.03, 0.08) p = 0.3111 0.05 (20.01, 0.11) p = 0.1059
Cystatin C(a) (mg/l) 0.02 (0.01, 0.03) p=0.0033 0.01 (0, 0.02) p = 0.1494
eGFR(a) (ml/min/1.73 m2) 0.88 (20.28, 2.03) p = 0.1367 0.27 (20.9, 1.45) p = 0.6509
BNP (pg/ml) 0.94 (0.85, 1.04) p = 0.2335 0.98 (0.88, 1.09) p = 0.7426
NT-proBNP (pg/ml) 1.03 (0.94, 1.13) p = 0.5874 1.07 (0.97, 1.18) p = 0.1584
*Regression models were fitted with novel risk factors as the outcome (all log transformed except for Fibrinogen, Cystatin C and eGFR) and log sST2 as the predictor.
Adjusted models include age, sex and their interaction.
Effect estimates are reported as the relative change in outcome (except for (a), presented as the absolute change), associated with a one standard deviation increase in
log sST2.
doi:10.1371/journal.pone.0047830.t003
Table 4. Associations between measures of atherosclerotic
burden (outcomes) and sST2 (predictor), univariately and
adjusted for age and sex*.
Outcome Effect Estimate (95% CI), p-value
Univariate Adjusted
c-IMT (mm) 1.03 (1.01, 1.05)
p=0.0002
1.01 (0.99, 1.02) p = 0.4223
Plaque Presence(b) 1.18 (1.00, 1.40)
p = 0.0539
1.01 (0.84, 1.21) p = 0.9195
*Regression models were fitted with log sST2 as the predictor. Adjusted models
include age, sex and their interaction. For c-IMT, data were log transformed and
a linear regression model was used. For plaque presence, a logistic regression
model was used.
Effect estimates are presented as the relative change in c-IMT and the odds
ratio for plaque presence associated with a one standard deviation increase in
log sST2.
doi:10.1371/journal.pone.0047830.t004
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The pSoBid study recruited subjects from least deprived and
most deprived areas within Glasgow. Therefore, we were also able
to investigate whether sST2 levels correlated with markers of
socio-economic status. sST2 levels were lower in individuals with a
higher salary, but did not correlate to other markers of social
deprivation. Clearly, further studies are needed to confirm our
observations but it is well known that socioeconomic factors are
associated with higher diabetes risk.
We found increased levels of circulating sST2 in men, and
increasing levels with age in women. These observations concur
with previous studies that demonstrated a link between sST2
levels, age and male gender [15,17]. A recent study investigated
the mechanism behind this gender bias by measuring association
of sST2 levels with androgen and oestrogen levels [28], but did not
find an independent association of sST2 with sex hormones in
healthy males and females. Therefore, the reason for the sex-
specific difference of sST2 plasma concentrations remains
uncertain, although it is now clear that men are at higher risk of
diabetes than women at any given BMI [29].
This is the first study to suggest a link between circulating
sICAM-1, a marker of endothelial dysfunction, and sST2 levels. A
large body of evidence points towards the involvement of
subclinical, low-grade inflammation and increased systemic levels
of acute phase proteins, cytokines and adhesion molecules in
patients with T2D [4]. Previous studies show that sICAM-1
predicts diabetes [30], and sICAM-1 associates more strongly with
diabetic risk than cardiovascular risk [31]. Furthermore, it has
been shown that endothelial cells can secrete sST2 in response to
treatment with various inflammatory mediators [32]. Thus, the
diabetic stressed vascular endothelium may be the source of the
increased plasma levels of sST2 seen in diabetic patients. Other
potential sources for sST2 secretion have been discussed by
Mildner and co-workers and include lung epithelial cells and
cardiac myocytes following activation with IL-1a/b and TNFa
[33].
Interestingly, sST2 did not correlate with classic markers linked
to CVD risk, including cholesterol, blood pressure, smoking, c-
IMT or plaque presence. Many studies have shown that sST2
levels are increased and predict mortality in patients with AMI
and/or heart failure [11,12,13,14]. Thus it is possible that this
increased mortality is not through an association with classic risk
factors but rather via other pathways reflective of metabolic status.
Of course, rather than a cause of vascular outcomes, sST2 could
be a marker of worsening vascular or associated metabolic status.
The mechanistic link between circulating sST2 and diabetes is
unclear at present but could be causal. The IL-33/ST2 pathway
may participate in the inflammatory and remodeling processes of
various tissues during diabetes. We have previously shown that IL-
33 exerts protective effects on glucose metabolism and obesity in
obese diabetic (ob/ob) mice [9]. Furthermore, IL-33 signaling
through ST2L is proposed to limit destructive Th17 responses in a
murine model of type 1 diabetes [34]. Increased levels of sST2
during diabetes may impair the protective effects of IL-33. It is
thus possible that sST2 is not only a biomarker but may contribute
to the pathogenesis of diabetes via IL-33 interactions.
There are some limitations to our study which merit consider-
ation. These analyses were not pre-specified as part of the main
pSoBid study protocol, so our findings should therefore be seen as
exploratory, and in need of replication in other populations.
Furthermore, we did not measure the ligand for sST2, IL-33.
There is a lack of robust and sensitive assays for IL-33 meaning
that this cytokine is difficult to detect in serum/plasma [15].
However, recent studies have highlighted the development of
multiplex assays to measure low abundance IL-33 in serum or
plasma and warrant further investigation in the context of diabetes
and CVD [35]. Finally, our results stem from a cross-sectional
study and thus we cannot infer predictive potential of sST2. Future
prospective and genetic studies may be useful to address the
predictive potential and causal role sST2 may have in cardiometa-
bolic outcomes.
In summary, our findings suggest that sST2 levels associate
more strongly with predictors of diabetes (triglycerides, glucose,
ICAM-1, ALT, GGT), than with established cardiovascular risk
predictors or surrogate vascular markers of atheroma (c-IMT or
plaque). Further mechanistic studies determining how sST2 is
linked to diabetes pathways, and how, in turn, these pathways may
influence mortality risks in individuals with vascular conditions,
would seem warranted and will likely offer new insights into the
inflammatory paradigm for type 2 diabetes.
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